Piramal Enterprises’ Pharma Solution division, a global leader in contract development and manufacturing is planning to invest $40 million in new equipment and next generation technologies.
The recent investments include areas such as Anti-body Drug Conjugation (ADC), Advanced Flow Reactor (ARF) and Biocatalysis Centre of Excellence systems. In addition to the investment of $40 million in new equipment and technologies, the company will also augment related infrastructure.
Piramal Pharma Solutions is an integrated solutions provider offering comprehensive range of services across the drug lifecycle. With a successful performance record of over four-decade in API supply (active pharmaceutical ingredients), drug products, drug discovery services, and with supply facilities in North America, Europe and Asia, it has established itself as a global market leader.
